Soligenix, Inc. (SNGX)
NASDAQ: SNGX · Real-Time Price · USD
0.3995
-0.0025 (-0.62%)
At close: Jun 18, 2026, 4:00 PM EDT
0.4100
+0.0105 (2.63%)
After-hours: Jun 18, 2026, 7:54 PM EDT
Soligenix Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
14
Market Cap
5.92M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 119.37K | -719.99K | -85.78% |
| Dec 31, 2023 | 839.36K | -109.55K | -11.55% |
| Dec 31, 2022 | 948.91K | 124.64K | 15.12% |
| Dec 31, 2021 | 824.27K | -1.54M | -65.07% |
| Dec 31, 2020 | 2.36M | -2.27M | -49.04% |
| Dec 31, 2019 | 4.63M | -611.53K | -11.67% |
| Dec 31, 2018 | 5.24M | -191.02K | -3.52% |
| Dec 31, 2017 | 5.43M | -5.02M | -48.01% |
| Dec 31, 2016 | 10.45M | 1.68M | 19.16% |
| Dec 31, 2015 | 8.77M | 1.73M | 24.50% |
| Dec 31, 2014 | 7.04M | 3.82M | 118.45% |
| Dec 31, 2013 | 3.22M | 79.53K | 2.53% |
| Dec 31, 2012 | 3.14M | -4.52M | -58.96% |
| Dec 31, 2011 | 7.66M | 5.72M | 293.44% |
| Dec 31, 2010 | 1.95M | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | 1.26M | -1.06M | -45.61% |
| Dec 31, 2006 | 2.31M | -762.72K | -24.80% |
| Dec 31, 2005 | 3.08M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Evogene | 1.84M |
| PMGC Holdings | 1.27M |
| Can-Fite BioPharma | 405.00K |
| AIM ImmunoTech | 94.00K |
| Silo Pharma | 72.10K |
| Cardio Diagnostics Holdings | 16.57K |
SNGX News
- 11 days ago - Soligenix to apply for vaccine development funding for Bundibugyo Ebola vaccine - TheFly
- 11 days ago - Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine - PRNewsWire
- 24 days ago - Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo - PRNewsWire
- 6 weeks ago - Soligenix reports Q1 EPS (28c) vs. (97c) last year - TheFly
- 6 weeks ago - Soligenix Announces Recent Updates and First Quarter 2026 Financial Results - PRNewsWire
- 6 weeks ago - Soligenix Quarterly report: Q1 2026 - Filings
- 6 weeks ago - Soligenix Earnings release: Q1 2026 - Filings
- 6 weeks ago - Soligenix price target lowered to $1.50 from $10 at Alliance Global - TheFly